Johnson & Johnson’s Tremfya Approved for Reimbursement in the UK and Germany

Johnson & Johnson announced on 6/13/2018 that the United Kingdom’s National Institute for Health and Care Excellence (NICE) has published positive guidance for Tremfya® (guselkumab), following its positive Final Appraisal Determination delivered on 2 May 2018.